The Covid-19 pandemic might yet delay US approval of Novartis's cholesterol-lowering project Leqvio − and then come the commercial questions.
The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.
Alkermes manages to shrug off yesterday’s complete response letter, but US knockbacks in 2020 are creeping up.
Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.